Aethlon Medical Inc (AEMD) - Net Assets

Latest as of June 2026: $5.20 Million USD

Based on the latest financial reports, Aethlon Medical Inc (AEMD) has net assets worth $5.20 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.24 Million) and total liabilities ($1.04 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Aethlon Medical Inc (AEMD) strategic asset index to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric Value
Current Net Assets $5.20 Million
% of Total Assets 83.38%
Annual Growth Rate 30.1%
5-Year Change -71.24%
10-Year Change 720.65%
Growth Volatility 272.27

Aethlon Medical Inc - Net Assets Trend (1997–2026)

This chart illustrates how Aethlon Medical Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Aethlon Medical Inc market capitalisation.

Annual Net Assets for Aethlon Medical Inc (1997–2026)

The table below shows the annual net assets of Aethlon Medical Inc from 1997 to 2026. Also explore Aethlon Medical Inc (AEMD) net asset momentum to track the company's year-over-year net asset growth rate.

Year Net Assets Change
2026-03-31 $4.89 Million -4.63%
2025-03-31 $5.12 Million -11.15%
2024-03-31 $5.77 Million -61.72%
2023-03-31 $15.06 Million -11.34%
2022-03-31 $16.99 Million +82.83%
2021-03-31 $9.29 Million +0.18%
2020-03-31 $9.28 Million +303.53%
2019-03-31 $2.30 Million -61.89%
2018-03-31 $6.03 Million +913.21%
2017-03-31 $595.41K -60.37%
2016-03-31 $1.50 Million +130.64%
2015-03-31 $651.38K +104.42%
2014-03-31 $-14.73 Million -61.08%
2013-03-31 $-9.14 Million +1.63%
2012-03-31 $-9.30 Million -55.56%
2011-03-31 $-5.98 Million -35.74%
2010-03-31 $-4.40 Million -11.47%
2009-03-31 $-3.95 Million -18.87%
2008-03-31 $-3.32 Million +53.15%
2007-03-31 $-7.09 Million -303.05%
2006-03-31 $-1.76 Million +42.63%
2005-03-31 $-3.07 Million +16.09%
2004-03-31 $-3.66 Million -0.82%
2003-03-31 $-3.63 Million -64.98%
2002-03-31 $-2.20 Million +10.89%
2001-03-31 $-2.47 Million -245.84%
2000-03-31 $-713.05K -1.21%
1999-03-31 $-704.50K -57409.88%
1998-03-31 $-1.23K -151.60%
1997-03-31 $2.37K --

Equity Component Analysis

This analysis shows how different components contribute to Aethlon Medical Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 17507113800.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (March 2026)

Component Amount Percentage
Common Stock $1.57K 0.03%
Other Comprehensive Income $-32.70K -0.67%
Other Components $180.02 Million 3684.27%
Total Equity $4.89 Million 100.00%

Aethlon Medical Inc Competitors by Market Cap

The table below lists competitors of Aethlon Medical Inc ranked by their market capitalization.

Company Market Cap
River and Mercantile UK Micro Cap Investment Company Ltd
LSE:RMMC
$1.02 Million
Gentlemens Equity S.A.
PA:MLGEQ
$1.02 Million
Edri-El
TA:EDRL
$1.02 Million
Value & Income Trust
LSE:VIP
$1.02 Million
General Shopping e Outlets do Brasil S.A.
SA:GSHP3
$1.02 Million
Wynnstay Group Plc
LSE:WYN
$1.02 Million
PHAXIAM Therapeutics S.A.
PA:PHXM
$1.01 Million
BioNeutra Global Corp
V:BGA
$1.01 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Aethlon Medical Inc's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2025 to 2026, total equity changed from 5,123,530 to 4,886,272, a change of -237,258 (-4.6%).
  • Net loss of 7,151,469 reduced equity.
  • New share issuances of 6,901,465 increased equity.
  • Other comprehensive income decreased equity by 15,570.

Equity Change Factors (2025 to 2026)

Factor Impact Contribution
Net Income $-7.15 Million -146.36%
Share Issuances $6.90 Million +141.24%
Other Comprehensive Income $-15.57K -0.32%
Other Changes $28.32K +0.58%
Total Change $- -4.63%

Book Value vs Market Value Analysis

This analysis compares Aethlon Medical Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.20x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has increased from 0.02x to 0.20x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1997-03-31 $69.82 $1.43 x
1998-03-31 $-36.03 $1.43 x
1999-03-31 $-17612.40 $1.43 x
2000-03-31 $-10186.46 $1.43 x
2001-03-31 $-33324.20 $1.43 x
2002-03-31 $-21544.47 $1.43 x
2003-03-31 $-24497.28 $1.43 x
2004-03-31 $-16766.87 $1.43 x
2005-03-31 $-8200.46 $1.43 x
2006-03-31 $-3377.13 $1.43 x
2007-03-31 $-9876.98 $1.43 x
2008-03-31 $-3622.97 $1.43 x
2009-03-31 $-3449.17 $1.43 x
2010-03-31 $-2915.39 $1.43 x
2011-03-31 $-3219.66 $1.43 x
2012-03-31 $-4567.87 $1.43 x
2013-03-31 $-459.61 $1.43 x
2014-03-31 $-577.72 $1.43 x
2015-03-31 $17.47 $1.43 x
2016-03-31 $30.48 $1.43 x
2017-03-31 $11.50 $1.43 x
2018-03-31 $73.47 $1.43 x
2019-03-31 $200.70 $1.43 x
2020-03-31 $275.55 $1.43 x
2021-03-31 $623.96 $1.43 x
2022-03-31 $928.83 $1.43 x
2023-03-31 $586.80 $1.43 x
2024-03-31 $183.58 $1.43 x
2025-03-31 $32.83 $1.43 x
2026-03-31 $7.25 $1.43 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Aethlon Medical Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -146.36%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 0.00%
  • • Asset Turnover: 0.00x
  • • Equity Multiplier: 1.30x
  • Recent ROE (-146.36%) is below the historical average (-130.50%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1997 -64.62% 0.00% 0.00x 1.15x $-1.77K
1998 0.00% -17.96% 26.57x 0.00x $-3.48K
1999 0.00% 0.00% 0.00x 0.00x $-282.23K
2000 0.00% 0.00% 0.00x 0.00x $-1.23 Million
2001 0.00% 0.00% 0.00x 0.00x $-4.18 Million
2002 0.00% 0.00% 0.00x 0.00x $-3.78 Million
2003 0.00% 0.00% 0.00x 0.00x $-2.10 Million
2004 0.00% 0.00% 0.00x 0.00x $-1.15 Million
2005 0.00% 0.00% 0.00x 0.00x $-1.79 Million
2006 0.00% 0.00% 0.00x 0.00x $-2.74 Million
2007 0.00% 0.00% 0.00x 0.00x $-5.32 Million
2008 0.00% 0.00% 0.00x 0.00x $-3.81 Million
2009 0.00% 0.00% 0.00x 0.00x $-5.69 Million
2010 0.00% 0.00% 0.00x 0.00x $-4.13 Million
2011 0.00% 0.00% 0.00x 0.00x $-5.11 Million
2012 0.00% -596.40% 1.62x 0.00x $-7.18 Million
2013 0.00% -397.72% 2.48x 0.00x $-3.98 Million
2014 0.00% -822.48% 0.96x 0.00x $-11.86 Million
2015 -1043.47% -891.51% 0.55x 2.12x $-6.86 Million
2016 -324.29% -549.53% 0.35x 1.70x $-5.02 Million
2017 -1222.01% -1855.78% 0.23x 2.90x $-7.34 Million
2018 -94.15% -3796.16% 0.02x 1.22x $-6.28 Million
2019 -255.45% -2697.88% 0.06x 1.70x $-6.44 Million
2020 -67.74% -980.33% 0.06x 1.10x $-7.31 Million
2021 -83.22% -1190.76% 0.06x 1.13x $-8.79 Million
2022 -60.80% -3540.90% 0.02x 1.13x $-12.13 Million
2023 -79.86% -2094.89% 0.03x 1.16x $-13.54 Million
2024 -211.71% 0.00% 0.00x 1.43x $-12.78 Million
2025 -261.31% 0.00% 0.00x 1.44x $-13.90 Million
2026 -146.36% 0.00% 0.00x 1.30x $-7.64 Million

Industry Comparison

This section compares Aethlon Medical Inc's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $561,953,781
  • Average return on equity (ROE) among peers: -16.96%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Aethlon Medical Inc (AEMD) $5.20 Million -64.62% 0.20x $1.02 Million
Abbott Laboratories (ABT) $4.82 Billion 39.04% 1.31x $177.99 Billion
Adagio Medical Holdings, Inc Common Stock (ADGM) $-132.02 Million 0.00% 0.00x $11.08 Million
Acutus Medical Inc (AFIB) $126.58 Million -80.56% 0.52x $903.35K
Adapthealth Corp (AHCO) $245.55 Million 0.85% 0.03x $800.36 Million
20/20 Biolabs, Inc. Common Stock (AIDX) $6.89 Million 30.07% 0.49x $4.97 Million
Allurion Technologies, Inc. (ALUR) $-34.28 Million 0.00% 0.00x $1.16 Million
Autonomix Medical, Inc. Common Stock (AMIX) $8.10 Million -140.88% 0.21x $4.00 Million
Artivion Inc (AORT) $7.30 Million 9.59% 0.70x $1.16 Billion
Apyx Medical Inc (APYX) $9.29 Million -10.75% 0.15x $126.79 Million

About Aethlon Medical Inc

NASDAQ:AEMD USA Medical Devices
Market Cap
$1.02 Million
Market Cap Rank
#30683 Global
#6236 in USA
Share Price
$1.43
Change (1 day)
-2.72%
52-Week Range
$0.53 - $5.75
All Time High
$1230.00
About

Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation, and other disease states. The company was founded in 1984 and is based in San Diego, California.